Table 1 Clinical characteristics of patients with CARDS and non-COVID-19 patients.
From: Reduced levels of pulmonary surfactant in COVID-19 ARDS
ID/patient group | Sex | Age (years) | BMI (kg/m2) | PaO2/FiO2 (mmHg)# | SAPS | Time from intubation to BAL procedure (h) | Time from COVID-19 symptom onset to BAL procedure (days) | Outcome |
|---|---|---|---|---|---|---|---|---|
CO1/Non-COVID-19 ARDS | M | 71 | 28 | 177 | 35 | 39 | NA | Survived |
CO2/Non-COVID-19 ARDS | M | 69 | 24 | 115 | 61 | 43 | NA | Died |
CO3/Non-COVID-19 ARDS | F | 68 | 22 | 175 | 44 | 13 | NA | Died |
CO4/Non-COVID-19 ARDS | M | 62 | 31 | 113 | 36 | 10 | NA | Died |
V01/CARDS | M | 40 | 21 | 83 | 58 | 65 | 10 | Survived |
V02/CARDS | F | 65 | 25 | 108 | 72 | 44 | 9 | Died |
V03/CARDS | M | 72 | 33 | 109 | 69 | 20 | 8 | Died |
V04/CARDS | M | 75 | 26 | 70 | 77 | 72 | 20 | Survived |
V05/CARDS | M | 59 | 22 | 115 | 56 | 41 | 14 | Survived |
V06/CARDS | M | 75 | 29 | 112 | 54 | 10 | 17 | Died |
V07/CARDS | M | 72 | 23 | 115 | 73 | 15 | 10 | Died |
V08/CARDS | M | 56 | 31 | 123 | 56 | 6 | 12 | Survived |
V09/CARDS | M | 69 | 25 | 150 | 55 | 12 | 11 | Died |
V10/CARDS | M | 72 | 25 | 125 | 60 | 28 | 9 | Died |
V11/CARDS | M | 67 | 26 | 86 | 59 | 18 | 14 | Survived |
